Clinical Supply Chain Management: Biotech – Phase III Study

Rapid Response and Flexibility Ensures Continual Drug Supply.

A small, US-based biotech company was planning a 5 year, phase III, randomised, double-blinded, placebo-controlled study. The study was conducted across multiple sites in the US involving 10,600 patients.This was a pivotal study for the client who initially contacted Almac for a better understanding of clinical trial supply management and to leverage our expertise to determine how much drug they would require.

Following discussions with our Supply Chain Management (SCM) team, they felt they lacked the resources and expertise internally and contracted Almac to provide core supply chain management services.The Almac SCM team assisted with devising optimal and cost effective packaging, distribution and drug accountability strategies throughout the life of the study.